|[January 18, 2013]
Research and Markets: PharmaPoint: Seasonal Influenza Vaccines - France Drug Forecast and Market Analysis
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/z8k68j/pharmapoint)
has announced the addition of GlobalData's new report "PharmaPoint:
Seasonal Influenza Vaccines France Drug Forecast and Market Analysis"
to their offering.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection. Currently, trivalent intramuscular
vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's
Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of
the market. However, with the entrance of vaccines with novel routes of
administration, such as AstraZeneca's intranasal FluMist and Sanofi's
Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the
adoption of such vaccines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will stealmarket share, patient share, and revenue from
the trivalent influenza vaccines currently available.
The French influenza vaccine market is valued at approximately $47.8
million in 2012. The projected drivers of sales growth include the
growth of the elderly population and introduction of quadrivalent
seasonal influenza vaccines. Sanofi is the market leader in France. The
French influenza manufacturer controls over a third of the influenza
vaccine market in this country, with a portfolio that includes trivalent
intramuscular influenza vaccines Vaxigrip and Mutagrip and an
intradermal vaccine, Intanza. Sanofi's home field advantage and novel
products have enabled it to dominate the French market.
Overview of seasonal influenza, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on the key drugs in France including product
description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in France from 2012 to 2022.
Analysis of the impact of key events as well the drivers and
restraints affecting the France seasonal influenza market.
Reasons to buy
Understand and capitalize by identifying products that are most likely
to ensure a robust return
Stay ahead of the competition by understanding the changing
competitive landscape for seasonal influenza
Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth
analysis of drug performance
Obtain sales forecast for drugs from 2012 to 2022 in France.
Product Profiles - Major Brands
- Fluzone ID (Intradermal)
For more information visit http://www.researchandmarkets.com/research/z8k68j/pharmapoint
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]